Abstract:Lung cancer has evidently drawn great attention from a variety of experts from many clinical related specialties in recent years including those in health administration departments. As is already known, non-small cell lung cancer (NSCLC) is predominant, accounting for approximately 85% of all lung cancers.1 It is a global concern and is the first cause of cancer-related death among males, and second among females. Unfortunately, the majority of patients with lung cancer are diagnosed at a progressive stage when surgical treatment is urgently required.2 In China, we are also faced with increasing lung cancer morbidity and ensuring patients receive surgical treatment in a timely manner via novel management. According to the eighth edition of the TNM lung cancer stage classification revealed in 2017,3 five-year survival rate declines dramatically both clinically and pathologically in patients diagnosed with stage I to stage IV. It is therefore crucially important to intervene scientifically at an early stage, which is also reflected in the eighth edition TNM lung cancer stage classification where stage I has been divided into four subtypes. This also provides a cost-effective suggestion for clinicians and administrators. The significant findings of the study are the high cost of surgery which make the early stages of the disease no less expensive than the advanced stages on a one-year timeline after disease has first been clinically suspected.4 We agree with these findings as for operable lung cancer patients on a one-year timeline, most of this period is spent on diagnostic auxiliary examination, surgery and short-term recovery which take most time and money, and subsequent neoadjuvant chemotherapy or other treatment costs are relatively lower. For those patients in which lung cancer is determined to be inoperable, most choose treatment covered by social medical insurance at our hospital, and the most expensive small-molecule target anticancer drugs are not included. Systematic lung cancer treatment is a long journey for both patient and clinician, and we are of the view that the sooner the patient receives surgical treatment once diagnosed the better, and it is still the most cost-effective way in the whole process. Nowadays, we are faced with a contradiction between soaring medical and increasing medical needs in China. Patients want to receive medical treatment as soon as possible in order to achieve the best possible outcome. Video-assisted thoracoscopic surgery (VATS) for early-stage lung cancer patients in the Day Surgery Center at our hospital is a case in point which solves this problem, as patients usually spend less than 24 hours in hospital. An effective day surgery program is a way to recover elective surgery, especially in the era of Covid-19. It greatly reduces waiting time and hospital infection, has no severe complication or surgically-related death, as previously reported in over 177 cases in our Day Surgery Center. The average surgery cost is 34 904 RMB which is about 15% less than traditional surgery, and does not include indirect costs. We are very interested in the results of this study because it gives us solid evidence for reference in our daily practice. Although it has limitations, it still has significant meaning for clinicians and policy makers. We greatly appreciate the assistance of the staff of the Day Surgery Center, West China Hospital, Sichuan University, and thank them for their efforts. No authors report any conflict of interest.

Analysis of Medical Costs for Patients with Advanced Non - Small Cell Lung Cancer

The Cost Of Treating Advanced Non-Small Cell Lung Cancer: Estimates From The Chinese Experience

PP71 Hospitalization Costs Associated with Advanced Non-Small Cell Lung Cancer in China: Real World Evidence from Jiangsu

Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China

Association Study of Survival Time and Hospitalization Expenses in Patients of Non-Small Cell Lung Cancer

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

PCN42 Health Care Utilization and Costs among Lung Cancer Patients in China

Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?

Trends of Clinical Features and Direct Medical Costs in Patients With Lung Cancer from 2000 to2009

Medical insurance payment schemes and patient medical expenses: a cross-sectional study of lung cancer patients in urban China

Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China.

Study on hospitalization expenses of elderly patients with lung cancer in the Western region of China

New Grey Correlation Analysis of Hospitalization Expenses of 600 Patients with Non-Small Cell Lung Cancer

Study on the Economic Burden of Lung Cancer Inpatients from One Tertiary Hospital in Shanghai

PCN43 STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

Estimated Annual Prevalence, Medical Service Utilization and Direct Costs of Lung Cancer in Urban China

Economic Analysis and Feasibility of Ambulatory Chemotherapy for Lung Cancer

Analysis on Hospitalization Expense of Five Kinds of Cancers and Its Influencing Factors

Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer

Response To: Estimated Direct Costs of Non‐small Cell Lung Cancer by Stage at Diagnosis and Disease Management Phase: A Whole‐disease Model

Measuring the Indirect Cost Associated with Advanced Non-Small Cell Lung Cancer: a Nationwide Cross-Sectional Study in China